65
Participants
Start Date
July 31, 2016
Primary Completion Date
April 30, 2017
Study Completion Date
November 14, 2017
Placebo
Participants received placebo matched to M2951 twice daily up to Day 84 during the double-blind treatment period.
M2951
Participants received 50 milligrams (mg) M2951 orally twice daily up to Day 84 during the double-blind treatment period.
M2951
Participants who received placebo matched to M2951 or M2951 in double-blind treatment period, received 50 mg M2951 orally twice daily up to 26-weeks during the open label extension period.
U.S. Medical Information, Billerica
Merck KGaA Communication Center, Darmstadt
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono Research & Development Institute, Inc.
INDUSTRY